Recruitment

Recruitment Status
Completed
Estimated Enrollment
15

Summary

Conditions
TTR-mediated Amyloidosis
Type
Interventional
Phase
Phase 2
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Min Age
18
Max Age
80
Gender
Both

Locations

Cleveland, Ohio, 44195
London, UK NW3 2PF
New York, New York, 10034
Boston, Massachusetts, 02155
Cleveland, Ohio, 44195
London, UK NW3 2PF
New York, New York, 10034
Boston, Massachusetts, 02155

Tracking Information

NCT #
NCT01981837
Collaborators
Not Provided
Investigators
Study Director: Jared Gollob, MD Alnylam Pharmaceuticals